These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34397109)

  • 41. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
    Chatterjee T; Chakravarty A; Chakravarty S
    Ann Hematol; 2018 May; 97(5):893-898. PubMed ID: 29453624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eculizumab for paroxysmal nocturnal haemoglobinuria.
    Parker C
    Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of cytochrome P450 1A2 in relation to hepatic iron accumulation in transfusion-dependent β-thalassaemia major patients.
    Shteyer E; Nitzan I; Godfarb A; Hemed N; Revel-Vilk S
    Vox Sang; 2015 Apr; 108(3):268-73. PubMed ID: 25471486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia.
    Biswas S; Ray R; Roy K; Bandyopadhyay A; Ghosh K; Bhattacharyya M
    Acta Haematol; 2019; 142(3):132-141. PubMed ID: 31352439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
    Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
    Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
    O'Connell T; Buessing M; Johnson S; Tu L; Thomas SK; Tomazos I
    Pharmacoeconomics; 2020 Sep; 38(9):981-994. PubMed ID: 32519233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major.
    al-Fawaz I; Ramia S
    Arch Dis Child; 1993 Nov; 69(5):594-6. PubMed ID: 8257183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 51. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW; Kulasekararaj AG
    Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyperhaemolysis in a pregnant woman with a homozygous β
    Jiwu L; Manna S; Lai M; Ying Z; Yanhui L
    Mol Genet Genomic Med; 2021 Jul; 9(7):e1696. PubMed ID: 33960744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
    Ansari SH; Lassi ZS; Khowaja SM; Adil SO; Shamsi TS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012064. PubMed ID: 30882896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
    Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease.
    Win N; Yeghen T; Needs M; Chen FE; Okpala I
    Hematology; 2004; 9(5-6):433-6. PubMed ID: 15763986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of BCL11A genetic variant (rs11886868) with severity in β-thalassaemia major & sickle cell anaemia.
    Dadheech S; Madhulatha D; Jainc S; Joseph J; Jyothy A; Munshi A
    Indian J Med Res; 2016 Apr; 143(4):449-54. PubMed ID: 27377501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
    Hillmen P; Muus P; Röth A; Elebute MO; Risitano AM; Schrezenmeier H; Szer J; Browne P; Maciejewski JP; Schubert J; Urbano-Ispizua A; de Castro C; Socié G; Brodsky RA
    Br J Haematol; 2013 Jul; 162(1):62-73. PubMed ID: 23617322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
    Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
    Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.
    Röth A; Bommer M; Hüttmann A; Herich-Terhürne D; Kuklik N; Rekowski J; Lenz V; Schrezenmeier H; Dührsen U
    Blood Adv; 2018 Oct; 2(19):2543-2549. PubMed ID: 30291112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.